A new protocol for multiple inhalation of IFN- successfully treats MDR-TB: a case study
OBJECTIVE: To test long-term conversion of sputum smears using the new Jena protocol.
DESIGN: Four MDR-TB patients were treated with aerosolized recombinant IFN- (rIFN-) twice weekly for 8 weeks and anti-tuberculosis drugs. Patients were monitored clinically and T-cell subpopulations were analyzed.
RESULTS: The treatment was well tolerated. All sputum smears cleared within 6–8 weeks, and radiological signs of recovery lasted in all patients for 73–106 months (the entire follow-up period). Before treatment, a patient with a 20+ year history of TB showed no T-cells; these cells appeared during treatment. The proportion of natural killer (NK) cells was enhanced during treatment and remained elevated. The proportion of CD4+/CD25+ T-cells in the blood rose after treatment and remained elevated at 2 and 10 months afterwards. No significant change in T-cell levels appeared in patients with a shorter history of TB, except for a tendency toward a slight increase in T-cells during treatment.
CONCLUSION: We invite further confirmation, but aerosolized rIFN- plus anti-microbial treatment cured MDR-TB in this case study. The optimal dosing schedule needs to be determined.
Document Type: Regular Paper
Affiliations: 1: Medical Clinics I, Department of Pneumology and Allergology/Immunology, Friedrich-Schiller University, Jena, Germany 2: Thoracic and Cardiovascular Surgery, Medical School, Loyola University, Maywood, Illinois, USA
Publication date: 2008-06-01
The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.
Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website
- Editorial Board
- Information for Authors
- Subscribe to this Title
- International Journal of Tuberculosis and Lung Disease
- Public Health Action
- Ingenta Connect is not responsible for the content or availability of external websites